Last reviewed · How we verify
Dihydroartemisinin-Piperaquine drug combination — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
Dihydroartemisinin-Piperaquine drug combination (Dihydroartemisinin-Piperaquine drug combination) — University of Yaounde 1.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Dihydroartemisinin-Piperaquine drug combination TARGET | Dihydroartemisinin-Piperaquine drug combination | University of Yaounde 1 | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Dihydroartemisinin-Piperaquine drug combination CI watch — RSS
- Dihydroartemisinin-Piperaquine drug combination CI watch — Atom
- Dihydroartemisinin-Piperaquine drug combination CI watch — JSON
- Dihydroartemisinin-Piperaquine drug combination alone — RSS
Cite this brief
Drug Landscape (2026). Dihydroartemisinin-Piperaquine drug combination — Competitive Intelligence Brief. https://druglandscape.com/ci/dihydroartemisinin-piperaquine-drug-combination. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab